Insilico Medicine flags H1 2026 profit with revenue surging as much as 287%

Key Takeaways:

Revenue expected at USD102.5M to USD106.5M, up as much as 287% YoY
Net profit of USD33.5M to USD39.5M marks first-half profitability
Pipeline advances with 31 PCCs and Rentosertib entering Phase III

Insilico Medicine (HKEX: 3696) expects to report first-half 2026 revenue of USD102.5 million to USD106.5 million, a year-on-year increase of as much as 287%, driven by global out-licensing deals and research collaborations, the generative AI-driven biotech company said Wednesday.

"The results validate our multi-pillar business model combining pipeline out-licensing, R&D collaborations, software out-licensing and internal pipeline advancement," Alex Zhavoronkov, founder, chairman and co-CEO at Insilico Medicine, said.

Net profit is expected to range from USD33.5 million to USD39.5 million for the six months ended June 30, compared with a loss in the prior-year period. Adjusted non-IFRS net profit is projected at USD45.5 million to USD51.5 million. The company did not disclose an EPS figure or dividend in the preliminary profit alert.

The strong performance reflects a surge in partnership activity during the period. Insilico announced out-licensing and drug discovery collaborations with Servier, Eli Lilly, SK Biopharmaceuticals, Qilu Pharmaceutical and Hygtia Therapeutics, among others. It also unlocked milestones in existing programs with Hisun Pharma, Menarini and TaiGen. On the technology side, the company launched two agentic AI systems — PandaClaw and LabClaw — and advanced its Science MMAI Gym foundation model training framework into revenue-generating collaborations with Liquid AI and Human Longevity.

Insilico's pipeline now includes 31 nominated preclinical candidate compounds across oncology, immunology, metabolism and central nervous system disorders, with 13 having achieved IND clearance. The company manages 10 clinical-stage programs, four wholly owned and six with partners. Rentosertib (ISM001-055), the world's first AI-empowered drug candidate for idiopathic pulmonary fibrosis, recently entered Phase III trials. Additional clinical milestones include first-subject dosing of Garutadustat (ISM5411) in a Phase IIa trial for inflammatory bowel disease and dual IND approvals for ISM8969, an NLRP3 inhibitor co-developed with Hygtia Therapeutics.

The positive profit alert signals that Insilico's AI-first, partnership-heavy strategy is translating into early profitability and a more predictable revenue base. Investors will watch for the final audited interim results, expected in August 2026, for detail on margin sustainability and the balance between collaboration income and internal R&D spend.

This article is for informational purposes only and does not constitute investment advice.